Finance

Lists
CRL:NYSE
Charles River Laboratories Intrtnl, Inc.
300,30 $
-1,53%
(-4,66) 1D
300,30 $
0,00% (0,00)
After hours
Closed: 7 հոկ, 16:00:11 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRL...
Open
303,38 $
High
305,18 $
Low
294,28 $
Mkt. cap
14,34 մլրդ
Avg. vol.
971,94 հզր
Volume
1,24 մլն
52-wk high
333,30 $
52-wk low
146,20 $
EPS
-4,85 $
Beta
1,40
Shares outstanding
47,74 մլն
No. of employees
19 հզր
Open
303,38 $
High
305,18 $
Low
294,28 $
Mkt. cap
14,34 մլրդ
Avg. vol.
971,94 հզր
Volume
1,24 մլն
52-wk high
333,30 $
52-wk low
146,20 $
EPS
-4,85 $
Beta
1,40
Shares outstanding
47,74 մլն
No. of employees
19 հզր
News stories
From web sources and news partners
Profile
Charles River Laboratories International, Incorporated is an American life sciences company and contract research organisation headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides goods and services that support the development of drugs, vaccines, and other therapeutics. Its operations span at least 20 countries, offering research models, drug discovery and safety assessment, and manufacturing and testing services to pharmaceutical, biotechnology, government, and other clients. Charles River Laboratories is a global provider of non-clinical drug development services, known for its role in toxicology studies, research animal models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration. The company has also been the subject of public scrutiny and regulatory attention over its use of research animals, including dogs, primates, and horseshoe crabs. As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL. Wikipedia
About Charles River Laboratories Intrtnl, Inc.
CEO-
Employees19 հզր
Founded1947
HeadquartersWilmington, Մասսաչուսեթս, Միացյալ Նահանգներ
Sector-
Websitecriver.com
Analyst ratings
Based on 17 analysts giving stock ratings to CRL in the past 3 months
Strong buy
Buy
15
Hold
2
Sell
0
12-month forecast
Based on 17 Wall Street analysts offering 12 month price targets for CRL in the last 3 months.
Highest
Current 300,30 $
357,00 $ (+18,88%)
Average
313,13 $ (+4,27%)
Lowest
219,00 $ (-27,07%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ryan Halsted
RBC Capital
Buy
Maintained
322,00 $
+7,2%
10/06/2026
Kevin Caliendo
UBS
Buy
Initiated
357,00 $
+18,9%
09/30/2026
Michael Ryskin
Bank of America Securities
Buy
Reiterated
-
-
09/28/2026
David Windley
Jefferies
Buy
Maintained
340,00 $
+13,2%
09/28/2026
Justin Bowers
Deutsche Bank
Buy
Reiterated
320,00 $
+6,6%
09/25/2026
Elizabeth Anderson CFA
Evercore ISI
Buy
Maintained
330,00 $
+9,9%
09/25/2026
Ann Hynes
Mizuho Securities
Hold
Maintained
295,00 $
-1,8%
09/25/2026
Eric Coldwell
Robert W. Baird
Buy
Maintained
334,00 $
+11,2%
09/25/2026
Luke Sergott
Barclays
Buy
Maintained
330,00 $
+9,9%
09/24/2026
Charles Rhyee
TD Cowen
Buy
Reiterated
325,00 $
+8,2%
09/25/2026
Jared Haase
William Blair
Buy
Reiterated
-
-
09/24/2026
Unknown Analyst
Stephens
Buy
Initiated
320,00 $
+6,6%
09/22/2026
Kallum Titchmarsh
Morgan Stanley
Buy
Reiterated
300,00 $
-0,1%
09/21/2026
David Toung
Argus Research
Buy
Reiterated
330,00 $
+9,9%
09/16/2026
Casey Woodring
J.P. Morgan
Buy
Upgraded
310,00 $
+3,2%
08/05/2026
Michael Luo CFA
CLSA
Hold
Downgraded
219,00 $
-27,1%
07/20/2026
Patrick B Donnelly
Citi
Buy
Maintained
265,00 $
-11,8%
07/08/2026
Max Smock
William Blair
Buy
Maintained
-
-
06/02/2026
Charles Weston
RBC Capital
Buy
Initiated
215,00 $
-28,4%
04/13/2026
Dan Leonard
UBS
Hold
Maintained
175,00 $
-41,7%
02/25/2026
Last report
05 օգս, 2026 թ.
Fiscal period
Q2 2026
3,02 $ / 2,74 $
+10,31%beat
Revenue / Est. (USD)
1,00 մլրդ / 977,20 մլն
+2,75%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
1,00 մլրդ
994,23 մլն
995,83 մլն
1,00 մլրդ
Cost of goods sold
652,72 մլն
665,36 մլն
672,79 մլն
625,06 մլն
Cost of revenue
652,72 մլն
665,36 մլն
672,79 մլն
625,06 մլն
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
173,64 մլն
192,02 մլն
149,12 մլն
214,18 մլն
Operating expense
201,05 մլն
284,04 մլն
164,46 մլն
227,27 մլն
Total operating expenses
853,77 մլն
949,40 մլն
837,25 մլն
852,33 մլն
Operating income
151,08 մլն
44,83 մլն
158,58 մլն
151,74 մլն
Other non operating income
-22,62 մլն
27,72 մլն
-123,11 մլն
25,99 մլն
EBT including unusual items
87,20 մլն
-294,10 մլն
-29,94 մլն
53,17 մլն
EBT excluding unusual items
104,48 մլն
35,18 մլն
8,62 մլն
148,43 մլն
Income tax expense
31,64 մլն
-17,81 մլն
-15,14 մլն
53,93 մլն
Effective tax rate
36,29%
6,06%
50,56%
101,43%
Other operating expenses
-
-
-
-
Net income
54,42 մլն
-276,56 մլն
-14,84 մլն
-1,48 մլն
Net profit margin
5,42%
-27,82%
-1,49%
-0,15%
Earnings per share
2,43
2,39
2,06
3,02
Interest and investment income
1,42 մլն
1,02 մլն
1,03 մլն
1,03 մլն
Interest expense
-25,40 մլն
-23,78 մլն
-26,74 մլն
-30,34 մլն
Net interest expenses
-23,98 մլն
-22,76 մլն
-25,71 մլն
-29,31 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
236,25 մլն
169,61 մլն
225,73 մլն
217,54 մլն
Gain or loss from assets sale
-
-
117,98 մլն
24,92 մլն
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google Apps